241 related articles for article (PubMed ID: 31546603)
1. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Mizuno Y; Yamamotoya T; Nakatsu Y; Ueda K; Matsunaga Y; Inoue MK; Sakoda H; Fujishiro M; Ono H; Kikuchi T; Takahashi M; Morii K; Sasaki K; Masaki T; Asano T; Kushiyama A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546603
[TBL] [Abstract][Full Text] [Related]
2. The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model.
Inoue MK; Yamamotoya T; Nakatsu Y; Ueda K; Inoue Y; Matsunaga Y; Sakoda H; Fujishiro M; Ono H; Morii K; Sasaki K; Masaki T; Suzuki Y; Asano T; Kushiyama A
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544662
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway.
Yang KJ; Choi WJ; Chang YK; Park CW; Kim SY; Hong YA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835220
[TBL] [Abstract][Full Text] [Related]
4. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Lee HJ; Jeong KH; Kim YG; Moon JY; Lee SH; Ihm CG; Sung JY; Lee TW
Am J Nephrol; 2014; 40(1):56-63. PubMed ID: 25034030
[TBL] [Abstract][Full Text] [Related]
6. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Omizo H; Tamura Y; Morimoto C; Ueno M; Hayama Y; Kuribayashi-Okuma E; Uchida S; Shibata S
Sci Rep; 2020 Jun; 10(1):9326. PubMed ID: 32518351
[TBL] [Abstract][Full Text] [Related]
7. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.
Kosugi T; Nakayama T; Heinig M; Zhang L; Yuzawa Y; Sanchez-Lozada LG; Roncal C; Johnson RJ; Nakagawa T
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F481-8. PubMed ID: 19458127
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
[TBL] [Abstract][Full Text] [Related]
9. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
10. Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.
Oda K; Miyamoto S; Kodera R; Wada J; Shikata K
J Diabetes Investig; 2023 Feb; 14(2):205-220. PubMed ID: 36308062
[TBL] [Abstract][Full Text] [Related]
11. Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.
Komers R; Xu B; Schneider J; Oyama TT
Br J Pharmacol; 2016 Sep; 173(17):2573-88. PubMed ID: 27238746
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
[TBL] [Abstract][Full Text] [Related]
13. Diabetic nephropathy in KK and KK-Ay mice.
Okazaki M; Saito Y; Udaka Y; Maruyama M; Murakami H; Ota S; Kikuchi T; Oguchi K
Exp Anim; 2002 Apr; 51(2):191-6. PubMed ID: 12012732
[TBL] [Abstract][Full Text] [Related]
14. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
[TBL] [Abstract][Full Text] [Related]
15. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Tsuda H; Kawada N; Kaimori JY; Kitamura H; Moriyama T; Rakugi H; Takahara S; Isaka Y
Biochem Biophys Res Commun; 2012 Oct; 427(2):266-72. PubMed ID: 22995295
[TBL] [Abstract][Full Text] [Related]
16. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
17. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
18. Anti-diabetic effects of globin digest and its active ingredient Leu-Ser-Glu-Leu in ICR mice, streptozotocin-induced diabetic mice and KK-Ay mice.
Nakaoka F; Sasakawa Y; Yamamoto K; Nakao M; Nakamura M; Tong C; Fukuhama C; Kagawa K
Life Sci; 2010 Mar; 86(11-12):424-34. PubMed ID: 20109472
[TBL] [Abstract][Full Text] [Related]
19. Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Sabán-Ruiz J; Alonso-Pacho A; Fabregate-Fuente M; de la Puerta González-Quevedo C
Antiinflamm Antiallergy Agents Med Chem; 2013; 12(1):94-9. PubMed ID: 23286293
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK.
Nomura J; Busso N; Ives A; Tsujimoto S; Tamura M; So A; Yamanaka Y
PLoS One; 2013; 8(9):e75527. PubMed ID: 24086554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
